References
- Cashman MW, Reutemann PA, Ehrlich A. Contact dermatitis in the United States: epidemiology, economic impact, and workplace prevention. Dermatol Clin. 2012;30:87–98.
- Diepgen TL, Agner T, Aberer W, et al. Management of chronic hand eczema. Contact Dermatitis. 2007;57:203–10.
- Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema – short version. J Dtsch Dermatol Ges. 2015;13:77–84.
- Coenraads PJ, Van Der Walle H, Thestrup-Pedersen K, et al. Construction and validation of a photographic guide for assessing severity of chronic hand dermatitis. Br J Dermatol. 2005;152:296–301.
- English JS, Wootton CI. Recent advances in the management of hand dermatitis: does alitretinoin work? Clin Dermatol. 2011;29:273–7.
- Fowler JF, Duh MS, Chang J, et al. A survey-based assessment of the prevalence and severity of chronic hand dermatitis in a managed care organization. Cutis. 2006;77:385–92.
- Moberg C, Alderling M, Meding B. Hand eczema and quality of life: a population-based study. Br J Dermatol. 2009;161:397–403.
- Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70:158–68.
- Cvetkovski RS, Rothman KJ, Olsen J, et al. Relation between diagnoses on severity, sick leave and loss of job among patients with occupational hand eczema. Br J Dermatol. 2005;152:93–8.
- English J, Graham-Brown R, de Sica Chapman A, Alexandroff AB. Everyday clinical experience of alitretinoin in the treatment of severe chronic hand eczema: seven case studies. Clin Exp Dermatol. 2011;36:1–2.
- Agner T, Andersen KE, Brandao FM, et al. EECDRG. Hand eczema severity and quality of life: a cross-sectional, multicentre study of hand eczema patients. Contact Dermatitis. 2008;59:43–7.
- Apfelbacher C, Molin S, Weisshaar E, et al. Characteristics and provision of care in patients with chronic hand eczema: updated data from the CARPE registry. Acta Derm Venereol. 2014;94:163–7.
- Hogan DJ, Dannaker CJ, Maibach HI. The prognosis of contact dermatitis. J Am Acad Dermatol. 1990;23:300–7.
- Charan UP, Peter CV, Pulimood SA. Impact of hand eczema severity on quality of life. Indian Dermatol Online J. 2013;4:102–5.
- Lerbaek A, Kyvik KO, Ravn H, et al. Clinical characteristics and consequences of hand eczema – an 8-year follow-up study of a population-based twin cohort. Contact Dermatitis. 2008;58:210–16.
- Thyssen JP, Johansen JD, Linneberg A, Menne T. The epidemiology of hand eczema in the general population-prevalence and main findings. Contact Dermatitis. 2010;62:75–87.
- Cvetkovski RS, Zachariae R, Jensen H, et al. Quality of life and depression in a population of occupational hand eczema patients. Contact Dermatitis. 2006;54:106–11.
- Veien NK, Hattel T, Laurberg G. Hand eczema: causes, course, and prognosis II. Contact Dermatitis. 2008;58:335–9.
- Landow K. Hand dermatitis. The perennial scourge. Postgrad Med. 1998;103:141.
- Watson W, Kapur S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2011;7:S4.
- Marshall D, Bridges JF, Hauber B, et al. Conjoint analysis applications in health—how are studies being designed and reported? An update on current practice in the published literature between 2005 and 2008. Patient. 2010;3:249–56.
- McFadden D, Train K. Mixed MNL models for discrete response. J Appl Econ. 2000;15:447–70.
- van Zuuren EJ, Apfelbacher CJ, Fedorowicz Z, et al. No high level evidence to support the use of oral H1 antihistamines as monotherapy for eczema: a summary of a Cochrane systematic review. Syst Rev. 2014;25:4053.
- Sidbury R, Davis DM, Cohen DE, et al. American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71:327–49.
- Van Houtven G, Johnson FR, Kilambi V, Hauber AB. Eliciting benefit-risk preferences and probability-weighted utility using choice-format conjoint analysis. Med Decis Making. 2011;31:469–80.
- Hauber AB, Fairchild AO, Johnson FR. Quantifying benefit-risk preferences for medical interventions: an overview of a growing empirical literature. Appl Health Econ Health Policy. 2013;11:319–29.
- van Til JA, Ijzerman MJ. Why should regulators consider using patient preferences in benefit-risk assessment? Pharmacoeconomics. 2014;32:1–4.
- Quartey G, Wang J. Statistical aspects in comparative benefit-risk assessment: challenges and opportunities for pharmaceutical statisticians. Pharm Stat. 2012;11:82–5.